Pfizer says analysis shows 3.8% of participants experienced fatigue
Tweet
Share
E-mail
FILE PHOTO: People walk past the Pfizer headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File Photo
NEW YORK (Reuters) - Pfizer Inc on Tuesday updated its analysis of the safety profile of its COVID-19 vaccine seen during its large, late-stage trial, saying that 3.8% of participants experienced fatigue after receiving a second dose of the shot.
It said the updated analysis was based on 8,000 trial participants. Pfizer said in a previous analysis that 3.7% of 6,000 volunteers had experienced fatigue.
Pfizer also added that there was a second adverse event with a frequency of at least 2% in the trial. The U.S. drugmaker said 2% of participants experienced headaches after the second shot.
(Reporting by Caroline Humer; Editing by David Clarke)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle licensing practices on EU antitrust regulator's radar, source says
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- MongoDB stock tumbles despite earnings beat on profit-taking
Create E-mail Alert Related Categories
General News, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
